Benoit Destenaves is an expert in personalised medicine and pharmacogenomics with more than 14 years of experience in the biotechnology and pharmaceutical industry.
Benoit specialises in the study of molecular biomarkers (DNA and RNA). He joined AstraZeneca's IMED Biotech unit in 2013 as Director, leading the Molecular Diagnostics labs and Pharmacogenomics. He heads a team of 14 scientists in charge of evaluation technology platforms for companion diagnostics, developing molecular diagnostics in partnership with diagnostic companies and supporting clinical testing. One of the key interests of his group is oncology, with a strong focus on novel approaches (e.g. ctDNA analysis, NGS).
He also leads company level strategic projects, including stratified/personalised medicine strategies, and strategic partnerships with diagnostic service providers, diagnostic companies and academic institutions.
Personalised healthcare: transforming the way we use medicine
Collaboration with the Montreal Heart Institute (MHI) in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes
Illumina collaboration to develop a next generation sequencing (NGS) platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio
AstraZeneca joins Genomics England consortium to accelerate the development of new diagnostics and treatments arising from the 100,000 Genomes Project
Personalised healthcare is a major step forward for patients and here at AstraZeneca, I truly believe we can make a difference for patients.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.